Therapeutic potentials of agonist and antagonist of adenosine receptors in type 2 diabetes

Rev Endocr Metab Disord. 2021 Jun 24. doi: 10.1007/s11154-021-09668-8. Online ahead of print.ABSTRACTType 2 diabetes has been a global health challenge over the decades and is among the leading causes of death. Several treatment approaches have been developed, but more effective and new therapies are still needed. The role of adenosine in glucose and lipid homeostasis has offered a different therapeutic approach. Adenosine mediates its physiological role through the activation of adenosine receptors. These adenosine receptors have been implicated in glucose and lipid homeostasis. The ability of agonists and antagonists of adenosine receptors to activate or inhibit the adenosine signalling cascade and thereby affecting the balance of glucose and lipid homeostasis has challenged the studies of agonists and antagonists of adenosine receptors, both preclinical and clinical, as potential anti-diabetic drugs. This review provides a background on different anti-diabetic therapeutic approaches, outlining the role of adenosine receptors in glucose and lipid homeostasis, and mechanisms underlying the action of agonists/antagonists of adenosine receptors as a therapeutic potential towards type 2 diabetes.PMID:34165671 | DOI:10.1007/s11154-021-09668-8

Source: ENDOCR REV - June 24, 2021 Category: Endocrinology Authors: Olakunle Sanni G Terre'Blanche Source Type: research